All I said is that I wait for news and data. And I stand by that. We’ve had Bank Mellon, Nant, and Axovant... and the share price remained stagnant and even sadly dwindled post R/S.
I’ll believe ‘material’ when a ‘material’ announcement comes. Because it is the most clear. That’s all.
Just because Benitec hasn’t killed anybody with their treatment doesn’t mean that non-efficacy and releases saying they want to improve delivery isn’t negative. It may not be negative regarding safety, but it surely isn’t positive in terms of it actually clinically impacting the targeted condition.
I just take actual PRs and releases to be the most accurate way to assess where they are. Everything else is somewhat anecdotal to me. Others may disagree, yet here we are at 5 cents.
We were never ever going to retrace, remember? I think we blew past that promise.
Add to My Watchlist
What is My Watchlist?